Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Biopharmaceutical company BioNTech SE (NASDAQ:BNTX) reported fourth-quarter and full-year 2024 earnings on Monday, March 10, that topped analysts' consensus expectations. It reported revenue of 1. ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

BioNTech reported Q4 earnings of €1.08 per share, beating the €0.38 consensus but down from €1.88 last year. 2025 revenue guidance of €1.7B-€2.2B trails the €2.57B consensus.

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.